Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.

Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Recent News

August 1, 2019

Viracta Strengthens Executive Management Team with New Appointments - Viracta Therapeutics, Inc. announced today that it has appointed Dan Chevallard as Chief Financial Officer and Xiaohu Deng, Ph.D. as Senior Vice President of Product Development. Read More

June 3, 2019

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting - Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion of the ongoing Phase 1b/2 clinical trial of nanatinostat in combination with the antiviral valganciclovir for the treatment of relapsed/refractory EBV-associated lymphomas. Read More

May 15, 2019

Viracta to Present New Clinical Results on Lead Epigenetic Drug Candidate Nanatinostat at the 2019 ASCO Annual Meeting - Viracta Therapeutics, Inc. announced today that it will present new clinical data during a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31 to June 4, 2019 in Chicago, IL. Read More

Events

June 19-21, 2019

Viracta will be doing a poster presentation at the 2019 ICML meeting in Lugano. Read More

May 31-June 4, 2019

Some of the team will be attending the Chicago, IL ASCO Meeting. Read More

May 29, 2019

Our CEO, Dr. Ivor Royston, will be winning a lifetime achievement award at the upcoming Xconomy San Diego Awards Gala. Read More

Recent News

August 1, 2019

Viracta Strengthens Executive Management Team with New Appointments - Viracta Therapeutics, Inc. announced today that it has appointed Dan Chevallard as Chief Financial Officer and Xiaohu Deng, Ph.D. as Senior Vice President of Product Development. Read More

June 3, 2019

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting - Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion of the ongoing Phase 1b/2 clinical trial of nanatinostat in combination with the antiviral valganciclovir for the treatment of relapsed/refractory EBV-associated lymphomas. Read More

May 15, 2019

Viracta to Present New Clinical Results on Lead Epigenetic Drug Candidate Nanatinostat at the 2019 ASCO Annual Meeting - Viracta Therapeutics, Inc. announced today that it will present new clinical data during a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31 to June 4, 2019 in Chicago, IL. Read More

Events

June 19-21, 2019

Viracta will be doing a poster presentation at the 2019 ICML meeting in Lugano. Read More

May 31-June 4, 2019

Some of the team will be attending the Chicago, IL ASCO Meeting. Read More

May 29, 2019

Our CEO, Dr. Ivor Royston, will be winning a lifetime achievement award at the upcoming Xconomy San Diego Awards Gala. Read More